Biomarker Study for Skin Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial focuses on understanding how blood samples from individuals with skin cancer can help predict the duration of cancer-free progression. Researchers aim to determine if specific blood markers can indicate the cancer's future course. Individuals with melanoma or non-melanoma skin cancers, such as basal cell carcinoma or squamous cell carcinoma, who are already receiving regular treatment, may be suitable candidates. Participants will provide blood samples for the study. As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research that could enhance future cancer predictions.
Do I need to stop my current medications to join the trial?
The trial does not specify whether you need to stop taking your current medications. It seems you can continue your regular treatment for skin cancer while participating.
What prior data suggests that this biomarker study is safe?
Research has shown that liquid biopsy, a method used in this study, is generally easy for participants to handle. Studies indicate that liquid biopsies, which involve taking a blood sample, are safe and carry fewer risks than traditional tissue biopsies. Past research reported no major safety issues with liquid biopsies in patients with melanoma and non-melanoma skin cancers. This evidence suggests that participants in this biomarker study can expect a low risk of side effects from the blood sampling process.12345
Why are researchers excited about this trial?
Researchers are excited about this trial because it focuses on identifying liquid biomarkers for melanoma and non-melanoma skin cancers. While current treatments often involve surgery, radiation, or targeted therapies, this approach aims to detect specific markers in the blood that could lead to earlier diagnosis and more personalized treatment plans. This method could potentially revolutionize how skin cancers are monitored and treated, offering a less invasive and more precise option for managing the disease. With the potential to improve early detection and tailor treatments to individual patients, this study could significantly enhance outcomes for those affected by skin cancer.
What evidence suggests that this biomarker study is effective for predicting progression-free survival in skin cancer?
Research shows that liquid biopsies, like those used in this study, could help track skin cancer. These tests analyze blood samples to detect cancer signs, potentially aiding doctors in predicting disease progression. Studies have shown that these blood tests can be used for diagnosing and monitoring melanoma. They could help doctors assess treatment effectiveness or detect cancer recurrence. Although promising, further research is needed to confirm their effectiveness for all skin cancer patients.23567
Who Is on the Research Team?
Vincent Ma, MD
Principal Investigator
University of Wisconsin, Madison
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Observation
Participants provide blood samples for biomarker analysis while undergoing regular treatment for skin cancer
Follow-up
Participants are monitored for changes in circulating tumor cells, tumor-derived exosomes, and circulating tumor DNA to assess progression-free survival and overall survival
What Are the Treatments Tested in This Trial?
Interventions
- Liquid Biomarker Study
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Participants with melanoma or non-melanoma skin cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Wisconsin, Madison
Lead Sponsor
National Center for Advancing Translational Sciences (NCATS)
Collaborator
National Cancer Institute (NCI)
Collaborator
Citations
Liquid Biomarker Study in Melanoma and Non- ...
This study is being done to study blood samples and compare them to other patient biospecimens and clinical outcomes.
Skin Cancer Research Goes Digital: Looking for Biomarkers ...
NMSCs are generally curable and rarely result in death or metastatic disease but can be locally destructive when treatment is inadequate or delayed. In contrast ...
Liquid biopsy as a potential tool for diagnosis and clinical ...
This review provides an overview of the ongoing research in the field and highlights the potential of liquid biopsy for the personalized treatment of melanoma, ...
4.
frontiersin.org
frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2024.1420360/fullLiquid biopsy for diagnostic and prognostic evaluation of ...
This review summarizes the potential of using liquid biopsy procedure in screening and monitoring the disease progression of melanoma.
5.
touchoncology.com
touchoncology.com/dermatological-cancers/journal-articles/current-and-future-applications-of-liquid-biopsy-in-melanoma/Current and Future Applications of Liquid Biopsy in ...
This study was pioneering in demonstrating the potential of CTCs as diagnostic biomarkers for melanoma, even in high-risk patients with other ...
Liquid Biomarker Study in Melanoma and Non-Melanoma ...
The goal of this observational study is to study blood samples and compare them to other biospecimens and clinical outcomes in participants who have ...
Clinical Relevance of Liquid Biopsy in Melanoma and ...
This review discusses the most recent data on liquid biopsy in patients with melanoma, the most common skin cancer with high prevalence in US and European ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.